JP2002533115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002533115A5 JP2002533115A5 JP2000591171A JP2000591171A JP2002533115A5 JP 2002533115 A5 JP2002533115 A5 JP 2002533115A5 JP 2000591171 A JP2000591171 A JP 2000591171A JP 2000591171 A JP2000591171 A JP 2000591171A JP 2002533115 A5 JP2002533115 A5 JP 2002533115A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- isolated polypeptide
- composition
- isolated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 229920001184 polypeptide Polymers 0.000 description 46
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 5
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 1
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 108010054971 parathyroid hormone-related protein (1-34) Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11457798P | 1998-12-31 | 1998-12-31 | |
| US60/114,577 | 1998-12-31 | ||
| PCT/US1999/031108 WO2000039278A2 (en) | 1998-12-31 | 1999-12-30 | Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533115A JP2002533115A (ja) | 2002-10-08 |
| JP2002533115A5 true JP2002533115A5 (enExample) | 2007-06-14 |
Family
ID=22356116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000591171A Pending JP2002533115A (ja) | 1998-12-31 | 1999-12-30 | Ｐｔｈ機能的ドメイン結合体ペプチド、それらの誘導体、および新規係留リガンド−レセプター分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080058505A1 (enExample) |
| EP (1) | EP1147133B1 (enExample) |
| JP (1) | JP2002533115A (enExample) |
| AT (1) | ATE403678T1 (enExample) |
| AU (1) | AU2486800A (enExample) |
| DE (1) | DE69939275D1 (enExample) |
| WO (1) | WO2000039278A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417333B1 (en) | 1998-11-25 | 2002-07-09 | The General Hospital Corporation | Modified human parathyroid hormone |
| US7169567B1 (en) | 1998-12-31 | 2007-01-30 | The General Hospital Corporation | Screening assay utilizing the PTH receptor |
| JP4703091B2 (ja) * | 2000-07-10 | 2011-06-15 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅに対して免疫原性である複数抗原性ペプチド |
| US7572765B2 (en) | 2001-07-23 | 2009-08-11 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
| DE50212514D1 (de) * | 2002-08-06 | 2008-08-28 | Aplagen Gmbh | Synthetische Mimetika von physiologischen Bindungsmolekülen |
| US8088734B2 (en) * | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| BRPI0814962B8 (pt) | 2007-08-01 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica |
| WO2010111617A2 (en) | 2009-03-27 | 2010-09-30 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| CN103002906B (zh) | 2010-05-13 | 2017-12-29 | 总医院有限公司 | 甲状旁腺激素类似物及其应用 |
| WO2012162547A2 (en) * | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
| US20200354428A9 (en) * | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US12233115B2 (en) | 2022-09-30 | 2025-02-25 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| US5527772A (en) * | 1987-10-20 | 1996-06-18 | Holick; Michael F. | Regulation of cell proliferation and differentiation using peptides |
| US5434246A (en) * | 1992-03-19 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5977070A (en) * | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| AU672790B2 (en) * | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| US5556940A (en) * | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| JP4486256B2 (ja) * | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体 |
| WO2000031137A1 (en) * | 1998-11-25 | 2000-06-02 | The General Hospital Corporation | Amino-terminal modified parathyroid hormone (pth) analogs |
| US6417333B1 (en) * | 1998-11-25 | 2002-07-09 | The General Hospital Corporation | Modified human parathyroid hormone |
| WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
-
1999
- 1999-12-30 DE DE69939275T patent/DE69939275D1/de not_active Expired - Fee Related
- 1999-12-30 AT AT99968197T patent/ATE403678T1/de not_active IP Right Cessation
- 1999-12-30 EP EP99968197A patent/EP1147133B1/en not_active Expired - Lifetime
- 1999-12-30 JP JP2000591171A patent/JP2002533115A/ja active Pending
- 1999-12-30 AU AU24868/00A patent/AU2486800A/en not_active Abandoned
- 1999-12-30 WO PCT/US1999/031108 patent/WO2000039278A2/en not_active Ceased
-
2007
- 2007-06-18 US US11/812,346 patent/US20080058505A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1318588C (zh) | 促骨生长素 | |
| EP0954588B1 (en) | Ob fusion protein compositions and methods | |
| DK2864360T3 (en) | TARGETED THERAPY | |
| Hoeck et al. | Identification of the major sites of phosphorylation in IGF binding protein‐3 | |
| JP2004500838A (ja) | 副甲状腺ホルモンおよび副甲状腺ホルモン関連タンパク質アンタゴニスト | |
| US20070020284A1 (en) | OB fusion protein compositions and methods | |
| HUT70459A (en) | Analogs of pth | |
| JP4541899B2 (ja) | ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ | |
| JP4334480B2 (ja) | α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン | |
| JP2002530111A5 (enExample) | ||
| JP2002167397A (ja) | ペプチド誘導体 | |
| JP2008500373A5 (enExample) | ||
| JP4871128B2 (ja) | 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ | |
| KR20010085847A (ko) | 펩티드 유도체 | |
| CN102405229A (zh) | 作为甲状旁腺激素(pth)受体激动剂的短链肽 | |
| EP1961765A1 (en) | Truncated PTH peptides with a cyclic conformation | |
| WO1997038014A1 (en) | Fibulin pharmaceutical compositions and related methods | |
| JPH0725799B2 (ja) | 高カルシウム体液性因子拮抗薬 | |
| JPH08509595A (ja) | 細胞分裂促進活性を有する短縮型インスリン様成長因子結合タンパク質 | |
| NZ310391A (en) | Polypeptides that stimulate bone growth | |
| EA005973B1 (ru) | Применение sarp-1 для лечения и/или предупреждения склеродермии | |
| WO1998026070A1 (en) | Bone stimulating factor | |
| EP1142580A1 (en) | Use of peptide | |
| US20030027753A1 (en) | Bone stimulating factor | |
| WO2000075185A1 (en) | Bone stimulating factor |